Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression =1%

Approval based on Phase 3 CheckMate -274 trial results showing that adjuvant treatment with Opdivo significantly reduced patients' risk of disease recurrence or death compared to placebo Opdivo

Related Keywords

Japan ,Norway ,Taiwan ,Iceland ,United States ,China ,Liechtenstein ,South Korea ,American ,Dana Walker ,Fred Witjes ,Opdivo Monotherapy ,Bristol Myers Squibb ,Alex Filicevas ,Instagram ,Company Opdivo ,American Society Of Clinical Oncology ,Linkedin ,Twitter ,Bristol Myers Squibb Company ,World Bladder Cancer Patient Coalition ,European Union ,Facebook ,European Commission ,Radboud Institute For Molecular Life Sciences ,Exchange Commission ,Youtube ,Ono Pharmaceutical Co ,Myers Squibb ,Hazard Ratio ,Confidence Interval ,Radboud Institute ,Molecular Life ,American Society ,Clinical Oncology ,Genitourinary Symposium ,New England Journal ,Bristol Myers ,World Bladder Cancer Patient ,Safety Profile ,Better Future ,Fatal Immune Mediated Adverse ,Full Prescribing Information ,Allogeneic Hematopoietic Stem Cell ,Multiple Myeloma ,Thalidomide Analogue ,Prescribing Information ,Ono Pharmaceutical ,Juno Therapeutics ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Bristol ,Myers ,Squibb ,Eceives ,European ,Commission ,Approval ,Opdivo ,Nivolumab ,Adjuvant ,Treatment ,Patients ,Eradically ,Nresected ,Thigh ,Risk ,Muscle ,Nvasive ,Urothelial ,Arcinoma ,Humor ,Fell ,